glp 1 and eating disorders New Insight: GLP‑1 medications—long used for diabetes—are now being explored for their role in disorder care, the implications are complex. Why it matters: At much higher doses than for diabetes Glp1 Use Higher in Eating

The gut microbiota modulate locomotion via vagus-dependent glucagon-like peptide-1 signaling

Phenotypegenotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism

While both peptides show remarkable promise individually, their potential combination raises critical questions about dosing protocols, safety considerations, and therapeutic rationale that demand careful examination

Final Disclaimer: This article is for informational purposes only

Activation of proinflammatory signaling by 4-hydroxynonenal-src adducts in aged kidneys [J]